Search

Your search keyword '"Ciardiello, F"' showing total 1,794 results
Start Over Author "Ciardiello, F"
1,794 results on '"Ciardiello, F"'

254. LBA-006 - BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer

Author

Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Gollerkeri, A., Maharry, K., Loupakis, F., Hong, Y., Steeghs, N., Guren, T., Arkenau, H., García Alfonso, P., Sandor, V., Christy-Bittel, J., Anderson, L., and Tabernero, J.

Published
2019
Full Text
View/download PDF

256. P-330 - Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data

Author

Vitale, P., Zanaletti, N., Vitiello, P., martinelli, e., Ciardiello, D., De Falco, V., Giunta, E., Poliero, L., Terminiello, M., Borrelli, C., Caputo, V., Arrichiello, G., Martini, G., Stefania, N., Famiglietti, V., Cardone, C., Ciardiello, F., and Troiani, T.

Published
2019
Full Text
View/download PDF

257. P-326 - Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience

Author

De Falco, V., Vitiello, P., Giunta, E., Ciardiello, D., Stefania, N., Cardone, C., Vitale, P., Zanaletti, N., Terminiello, M., Poliero, L., Borrelli, C., Caputo, V., Arrichiello, G., Mattera Iacono, V., Marrone, F., Famiglietti, V., Martinelli, E., Ciardiello, F., and Troiani, T.

Published
2019
Full Text
View/download PDF

259. Adjuvant Chemioradiotherapy in Patients with stage III or IV Radically Resected Gastric Cancer: a pilot study

Author

Orditura M., De Vita F., Muto P., Vitiello F., Murino P., Lieto E., Vecchione L., Romano A., Martinelli E., Ferraraccio F., Del Genio A., Ciardiello F., Galizia G., RENDA, ANDREA, Orditura, M., De Vita, F., Muto, P., Vitiello, F., Murino, P., Lieto, E., Vecchione, L., Romano, A., Martinelli, E., Renda, Andrea, Ferraraccio, F., Del Genio, A., Ciardiello, F., and Galizia, G.

Subjects
Gastric Cancer, Chemioradiotherapy
Abstract

Background: Adjuvant chemoradiotherapy does not represent the standard of care in patients with resected highrisk gastric cancer; however, results from phase 2 and randomizedtrials suggestimprovementin overall survival.We assessedthefeasibilityandtoxiceffectsofchemoradiotherapy as adjuvant treatment in locally advanced gastric cancer. Design: Pilot study. Setting: University hospital. Patients: Twenty-nine patients with T4Nor any TN23 gastric cancer previously treated with potentially curative surgery were enrolled. All of the patients received combined adjuvant chemotherapy with FOLFOX-4 (ie, a combination of folinic acid [leucovorin], fluorouracil, and oxaliplatin [Eloxatin]) for 8 cycles and concomitant radiotherapy (45 Gy in 25 daily fractions over 5 weeks). Radiotherapy was begun after the first 2 cycles of FOLFOX-4, which was reduced by 25% during the period of concomitant radiotherapy. Main Outcome Measures: Treatment toxic effects according to the National Cancer Institute–Common Toxicity Criteria classification, overall and disease-free survival rates, and identification of prognostic indicators. Results: All of the patients completed treatment. Severe hematologic and gastrointestinal toxic effects occurred in 10% and 33%, respectively. No acute hepatic or renal toxic effects were observed; 1 patient experienced severe neurotoxicity. Disease-free and overall survival rates at 1, 2, and 3 years were 79%, 35%, and 35% and 85%, 62.6%, and 50.1%, respectively, and were shown to be substantially better than those observed in untreated patients. Long-term outcome was related to TNM stage, basal serum tumor marker level, and, particularly, lymph node ratio. Conclusion: A multimodal approach with FOLFOX-4 and radiotherapy is feasible and effective for the treatment of patients with resected high-risk gastric cancer.

Published
2010

260. Perspectives in adjuvant therapy of gastric cancer

Author

De Vita F, Vecchione L, Galizia G, Di Martino N, Fabozzi T, CATALANO, Giuseppe, Ciardiello F, Orditura M, De Vita, F, Vecchione, L, Galizia, G, Di Martino, N, Fabozzi, T, Catalano, Giuseppe, Ciardiello, F, and Orditura, M

Published
2009

261. Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma&mdash

Author

Orditura, M., Galizia, G., Martino, N. Di, Ancona, E., Castoro, C., Pacelli, R., Morgillo, F., Rossetti, S., Gambardella, V., Farella, A., Laterza, M.M., Ruol, A., Fabozzi, A., Napolitano, V., Iovino, F., Lieto, E., Fei, L., Conzo, G., Ciardiello, F., and Vita, F. De

Subjects
genetic structures, gastroesophageal junction cancer, folfox4, Preoperative chemoradiotherapy
Abstract

To date, few studies of preoperative chemotherapy or chemoradiotherapy (crt) in gastroesophageal junction (gej) cancer have been statistically powered, indeed, gej tumours have thus far been grouped with esophageal or gastric cancer in phase iii trials, thereby generating conflicting results. We studied 41 patients affected by locally advanced Siewert type i and ii gej adenocarcinoma who were treated with a neoadjuvant crt regimen [folfox4 (leucovorin&ndash, 5-fluorouracil&ndash, oxaliplatin) for 4 cycles, and concurrent computed tomography&ndash, based three-dimensional conformal radiotherapy delivered using 5 daily fractions of 1.8 Gy per week for a total dose of 45 Gy], followed by surgery. Completeness of tumour resection (performed approximately 6 weeks after completion of crt), clinical and pathologic response rates, and safety and outcome of the treatment were the main endpoints of the study. All 41 patients completed preoperative treatment. Combined therapy was well tolerated, with no treatment-related deaths. Dose reduction was necessary in 8 patients (19.5%). After crt, 78% of the patients showed a partial clinical response, 17% were stable, and 5% experienced disease progression. Pathology examination of surgical specimens demonstrated a 10% complete response rate. The median and mean survival times were 26 and 36 months respectively (95% confidence interval: 14 to 37 months and 30 to 41 months respectively). On multivariate analysis, TNM staging and clinical response were demonstrated to be the only independent variables related to long-term survival. In our experience, preoperative chemoradiotherapy with folfox4 is feasible in locally advanced gej adenocarcinoma, but shows mild efficacy, as suggested by the low rate of pathologic complete response.

Published
2014
Full Text
View/download PDF

263. KRAS early testing: Consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an italian setting

Author

Barone, C., Giuliante, F., Adam, R., Pinto, C., Garufi, C., Folprecht, G., Falcone, Alfredo, Nuzzo, G., Van Cutsem, E., Ciardiello, F., Capussotti, L., Poston, G., Barone, C, Pinto, C, Normanno, N, Capussotti, L, Cognetti, F, Falcone, A, Mantovani, L, and Mantovani, LORENZO GIOVANNI

Subjects
Non-Clinical Medicine, Delphi Technique, Cost effectiveness, Colorectal cancer, Cost-Benefit Analysis, Cancer Treatment, lcsh:Medicine, Cetuximab, Colorectal Neoplasm, medicine.disease_cause, Cost Effectiveness, Antineoplastic Agent, Science Policy and Economics, Neoplasm Metastasis, lcsh:Science, Proto-Oncogene Protein, Multidisciplinary, Cost–benefit analysis, Health Care Costs, Cost-effectiveness analysis, Bevacizumab, Neoplasm Metastasi, Oncology, Italy, metastatic colorectal, Medicine, KRAS, Colorectal Neoplasms, Research Article, medicine.drug, Human, medicine.medical_specialty, KRAS testing, Science Policy, colorectal cancer, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Rectal Cancer, Proto-Oncogene Proteins p21(ras), Health Economics, Proto-Oncogene Proteins, Gastrointestinal Tumors, Cancer Detection and Diagnosis, Early Detection, medicine, Humans, Cost-Benefit Analysi, Intensive care medicine, neoplasms, Settore MED/06 - ONCOLOGIA MEDICA, Biochemistry, Genetics and Molecular Biology (all), business.industry, lcsh:R, kras, Cancers and Neoplasms, Chemotherapy and Drug Treatment, medicine.disease, ras Protein, digestive system diseases, Quality-adjusted life year, Surgery, Health Care Cost, Agricultural and Biological Sciences (all), ras Proteins, cetuximab or bevacizumab, lcsh:Q, Cost-Effectiveness, business
Abstract

KRAS testing is relevant for the choice of the most appropriate first-line therapy of metastatic colorectal cancer (CRC). Strategies for preventing unequal access to the test should be implemented, but their relevance in the practice is related to economic sustainability. The study adopted the Delphi technique to reach a consensus on several topics. Issues related to execution of KRAS testing were identified by an expert's board and proposed to 108 Italian oncologists and pathologists through two subsequent questionnaires. The emerging proposal was evaluated by decision analyses models employed by technology assessment agencies in order to assess cost-effectiveness. Alternative therapeutic strategies included most commonly used chemotherapy regimens alone or in combination with cetuximab or bevacizumab. The survey indicated that time interval for obtaining KRAS test should not exceed 15 days, 10 days being an optimal interval. To assure the access to proper treatment, a useful strategy should be to anticipate the test after radical resection in patients at high risk of relapse. Early KRAS testing in high risk CRC patients generates incremental cost-effectiveness ratios between 6,000 and 13,000 Euro per quality adjusted life year (QALY) gained. In extensive sensitivity analyses ICER's were always below 15,000 Euro per QALY gained, far within the threshold of 60,000 Euro/QALY gained accepted by regulatory institutions in Italy. In metastatic CRC a time interval higher than 15 days for result of KRAS testing limits access to therapeutic choices. Anticipating KRAS testing before the onset of metastatic disease in patients at high risk does not affect the sustainability and cost-effectiveness profile of cetuximab in first-line mCRC. Early KRAS testing may prevent this inequality in high-risk patients, whether they develop metastases, and is a cost-effective strategy. Based on these results, present joined recommendations of Italian societies of Oncology and Pathology should be updated including early KRAS testing. © 2014 Barone et al.

Published
2014

264. Enzastaurin inhibits tumors sensitive and resistant to anti-EGFR drugs

Author

GELARDI, Teresa, DAMIANO, VINCENZO, DANIELE, GENNARO, PEPE, STEFANO, BIANCO, ROBERTO, TORTORA, GIAMPAOLO, CAPUTO R, CIARDIELLO F, LAHN M, Gelardi, Teresa, Caputo, R, Damiano, Vincenzo, Daniele, Gennaro, Pepe, Stefano, Ciardiello, F, Lahn, M, Bianco, Roberto, and Tortora, Giampaolo

Subjects
resistance, EGFR, PKC, Enzastaurin
Published
2008

266. VEGF Receptor 1 contributes to resistance to anti-EGFR drugs in human cancer cells

Author

BIANCO, ROBERTO, TORTORA, GIAMPAOLO, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R, Albini A, Ryan A, Ciardiello F, Bianco, Roberto, Rosa, R, Damiano, V, Daniele, G, Gelardi, T, Garofalo, S, Tarallo, V, De Falco, S, Melisi, D, Benelli, R, Albini, A, Ryan, A, Ciardiello, F, and Tortora, Giampaolo

Subjects
resistance, EGFR, VEGFR-1
Published
2008

268. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study

Author

GRIDELLI C, GALLO C, CERIBELLI A, GEBBIA, Vittorio, GAMUCCI T, CIARDIELLO F, CAROZZA F, FAVARETTO A, DANIELE B, GALETTA D, BARBERA S, ROSETTI F, ROSSI A, MAIONE P, COGNETTI F, TESTA A, DI MAIO M, MORABITO A, PERRONE F, GECO INVESTIGATORS, GRIDELLI C, GALLO C, CERIBELLI A, GEBBIA V, GAMUCCI T, CIARDIELLO F, CAROZZA F, FAVARETTO A, DANIELE B, GALETTA D, BARBERA S, ROSETTI F, ROSSI A, MAIONE P, COGNETTI F, TESTA A, DI MAIO M, MORABITO A, PERRONE F, and GECO INVESTIGATORS

Subjects
trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer
Published
2007

269. Mechanisms of resistance to HER/erbB inhibitors

Author

BIANCO, ROBERTO, TORTORA, GIAMPAOLO, Damiano V, Gelardi T, Ciardiello F, Benjamin Bonavida, Bianco, Roberto, Damiano, V, Gelardi, T, Ciardiello, F, and Tortora, Giampaolo

Published
2007

271. Novel TLR9 agonist induces EGFR inhibition and synergistic antitumor activity with EGFR inhibitors

Author

DAMIANO, VINCENZO, BIANCO, ROBERTO, D'ARMIENTO, FRANCESCO PAOLO, LEONARDI, ANTONIO, DE PLACIDO, SABINO, TORTORA, GIAMPAOLO, CAPUTO R, BIANCO AR, AGRAWAL S, CIARDIELLO F, Damiano, Vincenzo, Caputo, R, Bianco, Roberto, D'Armiento, FRANCESCO PAOLO, Leonardi, Antonio, DE PLACIDO, Sabino, Bianco, Ar, Agrawal, S, Ciardiello, F, and Tortora, Giampaolo

Subjects
TLR9, EGFR, cetuximab
Abstract

Immunostimulating Toll-like receptor 9 (TLR9) agonists cause antitumor activity interfering also with cancer proliferation and angiogenesis by mechanisms still incompletely understood. We hypothesized that modified TLR9 agonists could impair epidermal growth factor receptor (EGFR) signaling and, by this means, greatly enhance EGFR inhibitors effect, acting on both the receptor targeting and the immunologic arm. EXPERIMENTAL DESIGN: We used a novel second-generation, modified, immunomodulatory TLR9 agonist (IMO), alone and in combination with the anti-EGFR monoclonal antibody cetuximab or tyrosine kinase inhibitor gefitinib, on the growth of GEO and cetuximab-resistant derivatives GEO-CR colon cancer xenografts. We have also evaluated the expression of several proteins critical for cell proliferation, apoptosis, and angiogenesis, including EGFR, mitogen-activated protein kinase, Akt, bcl-2, cyclooxygenase-2, vascular endothelial growth factor, and nuclear factor-kappaB. RESULTS: IMO inhibited GEO growth and signaling by EGFR and the other proteins critical for cell proliferation and angiogenesis. IMO plus the anti-EGFR antibody cetuximab synergistically inhibited tumor growth, signaling proteins, and microvessel formation. EGFR signaling inhibition by IMO is relevant because IMO cooperated also with EGFR tyrosine kinase inhibitor gefitinib in GEO tumors, while it was inactive against GEO-CR xenografts. On the other hand, IMO boosted the non-EGFR-dependent cetuximab activity, causing a cooperative antitumor effect in GEO-CR cells. Finally, combination of IMO, cetuximab and chemotherapeutic irinotecan eradicated the tumors in 90% of mice. CONCLUSION: IMO interferes with EGFR-related signaling and angiogenesis and has a synergistic antitumor effect with EGFR inhibitors, especially with cetuximab, boosting both the EGFR dependent and independent activity of this agent. Moreover, this therapeutic strategy could be translated in patients affected by colorectal cancer.

Published
2006

273. Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m)

Author

Garcia-Carbonero, R., primary, Van Cutsem, E., additional, Ciardiello, F., additional, Ychou, M., additional, Seitz, J.-F., additional, Hofheinz, R.D., additional, Arriaga, Y., additional, Verma, U., additional, Grothey, A., additional, Miriyala, A., additional, Kalmus, J., additional, Kappeler, C., additional, Falcone, A., additional, and Zaniboni, A., additional

Published
2016
Full Text
View/download PDF

276. blockade overcomes primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC)

Author

Martini, G., primary, Belli, V., additional, Vitiello, P.P., additional, Troiani, T., additional, Cardone, C., additional, Napolitano, S., additional, Desiderio, V., additional, Sforza, V., additional, Ferrara, M.L., additional, Papaccio, G., additional, Mele, L., additional, Liguori, G., additional, Botti, G., additional, Franco, R., additional, Morgillo, F., additional, Ciardiello, F., additional, and Martinelli, E., additional

Published
2016
Full Text
View/download PDF

277. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC

Author

Barlesi, F., primary, Park, K., additional, Ciardiello, F., additional, von Pawel, J., additional, Gadgeel, S., additional, Hida, T., additional, Kowalski, D., additional, Dols, M.C., additional, Cortinovis, D., additional, Leach, J., additional, Polikoff, J., additional, Gandara, D., additional, Barrios, C.H., additional, Chen, D.S., additional, He, P., additional, Kowanetz, M., additional, Ballinger, M., additional, Waterkamp, D., additional, Sandler, A., additional, and Rittmeyer, A., additional

Published
2016
Full Text
View/download PDF

280. HER2 activation and epithelial-mesenchymal transition (EMT) are involved in the acquired resistance to cetuximab in combination with either regorafenib or refametinib

Author

Vitiello, P.P., primary, Martini, G., additional, Belli, V., additional, Cardone, C., additional, Sforza, V., additional, Ferrara, M.L., additional, Napolitano, S., additional, Della Corte, C.M., additional, Zanaletti, N., additional, Vitale, P., additional, Pompella, L., additional, Morgillo, F., additional, Troiani, T., additional, Ciardiello, F., additional, and Martinelli, E., additional

Published
2016
Full Text
View/download PDF

281. gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study

Author

Van Cutsem, E., primary, Yoshino, T., additional, Lenz, H.-J., additional, Lonardi, S., additional, Falcone, A., additional, Limon, M.L., additional, Saunders, M.P., additional, Sobrero, A., additional, Maiello, E., additional, Park, Y.S., additional, Monteagudo, R. Ferreiro, additional, Hong, Y.S., additional, Tomasek, J., additional, Taniguchi, H., additional, Ciardiello, F., additional, Hocke, J., additional, Oum'hamed, Z., additional, Vlassak, S., additional, Studeny, M., additional, and Tabernero, J., additional

Published
2016
Full Text
View/download PDF

282. SYM004, a novel generation anti-EGFR inhibitor, is able to overcome acquired resistance to cetuximab such as MET activation, ERBB2 amplification and EGFR mutations, in colorectal cancer models

Author

Napolitano, S., primary, Belli, V., additional, Castellone, M.D., additional, Parascandolo, A., additional, Martinelli, E., additional, Martini, G., additional, Cardone, C., additional, Morgillo, F., additional, Orditura, M., additional, Ciardiello, F., additional, and Troiani, T., additional

Published
2016
Full Text
View/download PDF

285. Neutrophil to lymphocyte ratio is a predictor of outcome in metastatic pancreatic cancer patients (MPC) treated with nab-paclitaxel and gemcitabine

Author

Ventriglia, J., primary, Petrillo, A., additional, Huerta, M., additional, Laterza, M.M., additional, Savastano, B., additional, Gambardella, V., additional, Tirino, G., additional, Pompella, L., additional, Diana, A., additional, Febbraro, A., additional, Troiani, T., additional, Orditura, M., additional, Cervantes, A., additional, Ciardiello, F., additional, and De Vita, F., additional

Published
2016
Full Text
View/download PDF

286. Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by next generation sequencing (NGS) in the CAPRI- GOIM trial

Author

Martinelli, E., primary, Cardone, C., additional, Troiani, T., additional, Normanno, N., additional, Pisconti, S., additional, Bordonaro, R., additional, Francesco, G., additional, Biglietto, M., additional, Barone, C., additional, Rachiglio, A.M., additional, Montesarchio, V., additional, Tonini, G., additional, Cinieri, S., additional, Rizzi, D., additional, Febbraro, A., additional, Latiano, T.P., additional, Modoni, G., additional, Giuseppe, C., additional, Maiello, E., additional, and Ciardiello, F., additional

Published
2016
Full Text
View/download PDF

291. health economics The effect of financial difficulties on clinical outcomes in Italian cancer patients: A pooled analysis of 16 academic prospective clinical trials

Author

Perrone, F., primary, Jommi, C., additional, Di Maio, M., additional, Gimigliano, A., additional, Gridelli, C., additional, Pignata, S., additional, Ciardiello, F., additional, Nuzzo, F., additional, de Matteis, A., additional, Del Mastro, L., additional, Bryce, J., additional, Daniele, G., additional, Morabito, A., additional, Piccirillo, M.C., additional, Rocco, G., additional, Guizzaro, L., additional, and Gallo, C., additional

Published
2016
Full Text
View/download PDF

292. Efficacy of sequential treatment with first, second and third generation EGFR inhibitors and role of Hedgehog pathway in the acquisition of resistance in in vivo NSCLC models

Author

Corte, C.M. Della, primary, Papaccio, F., additional, Viscardi, G., additional, Esposito, G., additional, Fasano, M., additional, Castellone, M.D., additional, Parascandolo, A., additional, De Vita, F., additional, Orditura, M., additional, Ciardiello, F., additional, and Morgillo, F., additional

Published
2016
Full Text
View/download PDF

294. Transforming growth factor beta receptor (TGF&bgr;R) pathway is involved in ligand independent transactivation of AXL receptor in colorectal cancer (CRC) cell lines

Author

Franzese, E., primary, Martini, G., additional, Cardone, C., additional, Troiani, T., additional, Sforza, V., additional, Ferrara, M.L., additional, Belli, V., additional, Vitiello, P.P., additional, Napolitano, S., additional, Zanaletti, N., additional, Vitale, P., additional, De Vita, F., additional, Orditura, M., additional, Morgillo, F., additional, Ciardiello, F., additional, and Martinelli, E., additional

Published
2016
Full Text
View/download PDF

296. The combination of GDC-0980, a PI3K/mTOR kinase inhibitor and BAY-86-9766, a MEK inhibitor is able to induce cell growth inhibition of HER2 positive Trastuzumab resistant gastric cancer cell lines

Author

Savastano, B., primary, laterza, M.M., additional, Capasso, A., additional, Belli, V., additional, Ventriglia, J., additional, Petrillo, A., additional, Tirino, G., additional, Pompella, L., additional, Morgillo, F., additional, Martinelli, E., additional, Orditura, M., additional, Ciardiello, F., additional, and De Vita, F., additional

Published
2016
Full Text
View/download PDF

298. The effect of financial difficulties on clinical outcomes in Italian cancer patients: a pooled analysis of 16 academic prospective clinical trials

Author

Perrone, F., primary, Jommi, C., additional, Di Maio, M., additional, Gimigliano, A., additional, Gridelli, C., additional, Pignata, S., additional, Ciardiello, F., additional, Nuzzo, F., additional, de Matteis, A., additional, Del Mastro, L., additional, Bryce, J., additional, Daniele, G., additional, Morabito, A., additional, Piccirillo, M.C., additional, Rocco, G., additional, Guizzaro, L., additional, and Gallo, C., additional

Published
2016
Full Text
View/download PDF

299. Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial

Author

Maiello, E., primary, Martinelli, E., additional, Cardone, C., additional, Troiani, T., additional, Normanno, N., additional, Pisconti, S., additional, Bordonaro, R., additional, Giuliani, F., additional, Biglietto, M., additional, Barone, C., additional, Rachiglio, A.M., additional, Montesarchio, V., additional, Tonini, G., additional, Cinieri, S., additional, Rizzi, D., additional, Febbraro, A., additional, Latiano, T., additional, Modoni, G., additional, Colucci, G., additional, and Ciardiello, F., additional

Published
2016
Full Text
View/download PDF

300. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2 amplified gastric cancer (GC) cell lines

Author

Laterza, M.M., primary, Belli, V., additional, Ciaramella, V., additional, Martinelli, E., additional, Morgillo, F., additional, Ventriglia, J., additional, Savastano, B., additional, petrillo, A., additional, TIRINO, G., additional, POMPELLA, L., additional, Diana, A., additional, Orditura, M., additional, Ciardiello, F., additional, and DE VITA, F., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results